Male androgenetic alopecia (Part II)

Journal of Men's Health and Gender

Volumn 2, Issue 1, 2005, Pages 38-44

  Sinclair, Rodney D ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Androgenetic; Bald; Finasteride; Minoxidil; Propecia

Indexed keywords

ANTIANDROGEN; CALCIUM; DIAZOXIDE; FINASTERIDE; FLURIDIL; MINOXIDIL; PINACIDIL; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

BONE DENSITY; BONE MINERAL; CALCIUM CELL LEVEL; CHEMICAL TERATOGENESIS; CONTACT ALLERGY; CONTACT DERMATITIS; DIZZINESS; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GYNECOMASTIA; HAIR FOLLICLE; HAIR GROWTH; HAIR LOSS; HUMAN; HYPERTRICHOSIS; LIBIDO DISORDER; MALE TYPE ALOPECIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; SKIN IRRITATION; TACHYCARDIA;

EID: 23244433782     PISSN: 15718913     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhg.2004.12.010     Document Type: Review

References (38)

1. D.R. Nyholt, N.A. Gillespie, A.C. Heath, and N.G. Martin Genetic basis of male pattern baldness J Invest Dermatol 121 6 2003 1561 1564
2. B.L. Devine, R. Fife, and P.M. Trust Minoxidil for severe hypertension after failure of other hypotensive drugs Br Med J 2 1977 667 669
3. V.E. Prive Drug Therapy: Treatment of Hair Loss NEJM 341 1999 964 973
4. J.T. Headington, and E. Novak Clinical and histologic studies of male pattern baldness treated with topical minoxidil Curr Ther Res 36 1984 1098 1106
5. M. Li, A. Marubayashi, Y. Nakaya, K. Fukui, and S. Arase Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: Possilbe involvement of sulfonylurea receptor 2B as a target of minoxidil J Invest Dermatol 117 2001 1594 1600
6. H.I. Kats, N.T. Hien, S.E. Prawer, and S.J. Goldman Long-term efficacy of topical minoxidil in male pattern baldness J Am Acad Dermatol 16 1987 648 652
7. R.L. Rietschel, and S.H. Duncan Safety and efficacy of topical minoxidil in the management of androgenetic alopecia J Am Acad Dermatol 16 1987 677 685
8. E.A. Olsen, M.S. Weiner, I.A. Amara, and E.R. DeLong Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil J Am Acad Dermatol 22 1990 643 646
9. V.H. Price, E. Menefee, and P.C. Strauss Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment J Am Acad Dermatol 41 1999 717 721
10. J. Shapiro, and V.H. Price Hair regrowth: Therapeutic agents Dermatol Ther 16 1998 341 356
11. C. Wilson, V. Walkden, S. Powell, S. Shaw, J. Wilkinson, and R.P.R. Dawber Contact dermatitis in reaction to 2% topical minoxidil solution J Am Acad Dermatol 24 1991 643 646
12. D. Van Neste, V. Fuh, P. Snachez-Pedreno, E. Lopez-Bran, H. Wolff, and D. Whiting Finasteride increases anagen hair in men with androgenetic alopecia Br J Dermatol 143 2000 804 810
13. D. Whiting, J. Waldstreicher, M. Sanchex, and K.D. Kaufman Measuring reversal of hair miniaturisation in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and post menopausal women J Invest Dermatol 4 1999 282 284
14. V.H. Price, E. Menefee, M. Sanchex, P. Ruane, and K.D. Kaufman Changes in hair weisth and ahir count in men with androgenetic alopecia after treatment with finasteride 1 mg daily J Am Acad Dermatol 46 2002 517 523
15. L. Drake, M. Hordinsky, and V. Fiedler The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia J Am Acad Dermatol 41 1999 550 554
16. J.N. Roberts, V. Fiedler, and J. Imperato-McGinley Clinical dose ranging studies with finasteride, a type 2 5α reductase inhibitor, in men with male pattern hair loss J Am Acad Dematol 41 1999 555 563
17. K.D. Kaufman, E.A. Olsen, D. Whiting, R. Savin, R. De Villex, and W. Bergfeld Finasteride in the treatment of men with androgenetic alopecia J Am Acad Dermatol 39 1998 578 579
18. J. Leyden, F. Dunlap, B. Miller, P. Winters, M. Lebwohl, and D. Hecker Finasteride in the treatment of men with frontal male pattern hair loss J Am Acad Dermatol 40 1999 930 937
19. The Finasteride Male Pattern Hair Loss Study G. Long-term (5year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002:12:38-49
20. (Kaufman K. Long term (5 year) multinational experience with finasteride in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002:12;38-49).
21. D.B. Stough, N.A. Rao, K.D. Kaufman, and C. Mitchell Finasteride improves male pattern hair loss in a randomized study in identical twins Eur J Dermatol 12 2002 32 37
22. K.E. Thai, and R.D. Sinclair Finasteride for female androgenetic alopecia Br J Dermatol. 147 4 2002 812 813
23. A. Tosti, B.M. Piraccini, and M. Soli Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia J Eur Acad Dermatol Venereol 15 2001 418 421
24. H. Matzkin, M. Barak, and Z. Braf Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia Br J Urol 78 1996 405 408
25. D.W. Keetch, G.L. Andriole, T.L. Ratliff, and W.J. Catalona Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin or watchful waiting Urology 50 1997 901 905
26. G.L. Andriole, H.A. Guess, and J.I. Epstein Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial Urology 52 1998 195 202
27. Physicians circular for Propecia. In. West Point: Merck; 1997.
28. R.D. Sinclair, and R.P.R. Dawber Androgenetic alopecia in men and women Clin Dermatol 19 2001 167 178
29. R.M. Trueb, and P. Itin Photographic documentation of the effectiveness of 1 mg. Oral finasteride in treatment of androgenetic alopecia in the man in routine general practice in Switzerland Schweiz Rundsch Med Prax 29 90 2001 2087 2093
30. S.R. Tollin, H.N. Rosen, K. Zurowski, B. Saltzman, A.J. Zeind, and S. Berg Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia - a Clinical Research Center study J Clin Endocrinol Metab 81 1996 1031 1034
31. A.M. Matsumoto, L. Tenover, M. McClung, D. Mobley, J. Geller, and M. Sullivan The long-term effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: Results of a 4-year placebo controlled trial J Urol 176 2002 2105 2108
32. M.S. Wade, and R.D. Sinclair Reversible painful gynaecomastia induced by low dose finasteride (1 mg/day) Austral J Dermatol 41 2000 5
33. J. Ferrando, R. Grimalt, M. Alsina, F. Bulla, and E. Manasievska Unilateral gynaecomastia induced by treatment with 1 mg of oral finasteride Arch Dermatol 138 2002 543 544
34. A. Chong, P. Foley, R. Sinclair, and R. Marks Viewpoints in Dermatology: Second Cite. A review of recent journal highlights Clin Exp Dermatol 29 2004 107 109
35. M. Sovak, A.L. Seligson, and R. Kucerova Fluridi, a rationally designed topical agent for androgenetic alopecia: First clinical experience Dermatol Surg 28 2002 678 685
36. M.E. Sawaya Novel agents for the treatment of androgenetic alopecia Semin Cutan Med Surg 17 1998 276 283
37. Dutasteride (Avodart) for Benign Prostatic Hyperplasia. Med Lett Drugs Ther 2002; 44:109-110.
38. R.C. Shiell Modern hair restoration surgery Clin Dermatol 19 2001 179 187